University of Utah Research Foundation

Medical College of Georgia Research Institute, Inc.

University of Kentucky Research Foundation

Balamurali Krishna Ambati

Bruce Kent Gale

Hironori Uehara

Srinivas Rao Chennamaneni

Nirbhai Singh

Shivan Amin

Jayakrishna Ambati

Randon Michael Burr

Sarah A Molokhia

Santosh Muddana

An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.

Treatment of myopic progression

An ophthalmic composition or dosage form can include a therapeutically effective amount of a cross-linking agent and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat an ophthalmic condition by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.

Cross-linking agents and associated methods

Devices, systems, and methods for delivery of an active agent from the lens capsule to a posterior segment of the eye of a subject can include an intraocular active agent delivery device including an active agent dispersed within a biodegradable active agent matrix. The active agent includes dexamethasone and the delivery device is adapted to fit within a lens capsule or ciliary sulcus of an eye. The delivery device can be inserted into the lens capsule or ciliary sulcus of an eye during cataract surgery or for treatment of uveitis.

Intraocular drug delivery device and associated methods

Devices, systems, and methods for delivery of an active agent into the eye of a subject can include an intraocular active agent delivery device including an active agent dispersed within a biodegradable active agent matrix. The active agent includes dexamethasone and the delivery device is adapted to fit within a lens capsule or ciliary sulcus of an eye. The delivery device can be inserted into the lens capsule or ciliary sulcus of an eye during cataract surgery or for treatment of uveitis.

An intraocular active agent delivery device can include an active agent homogenously combined with a biodegradable active agent matrix such that the entire delivery device is homogenous. The homogenous delivery device can have a shape and size to fit within a lens capsule or ciliary sulcus of an eye and provide a therapeutically effective amount of the active agent to the eye. The biodegradable active agent matrix can be formulated to provide sustained release of the therapeutically effective amount of the active agent during a release period. In some examples, the active agent can include dexamethasone.

Various methods and compositions relating to vascular endothelial growth factor receptor 2 (VEGFR2) are provided. In one aspect, a method of increasing expression of the soluble form of VEGFR2 (sVEGFR2) in a subject can include binding an antisense morphoiino to an exon13-intron13 splicing site of VEGFR2 mRNA such that the VEGFR2 niRNA is spliced into a sVEGFR2 isoform.

Morpholinos, morpholino upregulating, and associated methods

Methods of inhibiting lymphangiogenesis and/or angiogenesis in a subject are provided. In one aspect, for example, a method of inhibiting angiogenesis in a subject can include binding an antisense morpholino to an mRNA splicing site of VEGFR1 selected from exon13_intron13 junction, intron13_exon14 junction, or a combination thereof. In another aspect, the morpholino includes a member selected from VEGFR1_MOe13, VEGFR1_MOi13, or a combination thereof.

Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization

The present invention provides an intraceptor that interacts with and decreases activity of with VEGF and/or a VEGFR for the treatment of angiogenesis-related conditions. The present invention further provides pharmaceutical compositions, and methods of use thereof, for the treatment and prevention of an angiogenesis-related condition using said intraceptors. The invention further provides for nucleic acids encoding said intraceptors.

Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptors

This invention relates to compounds, compositions, and methods for the treatment of traits, diseases and conditions that respond to the modulation of angiogenic growth factor bioavailability or biological activity.

Modulation of angiogenesis

Devices, systems, and methods for delivery of an active agent into the eye of a subject can include an ocular active agent delivery device () having an active agent reservoir () disposed in an annular body (), the annular body () being configured to fit inside of a lens capsule and at least partially encircling a line of sight of an intraocular lens within the lens capsule.

The present invention provides devices, systems, and methods for delivery of an active agent into the eye of a subject. In one aspect, for example, an ocular active agent delivery device () can include an active agent reservoir () disposed in an annular housing (), the annular housing () being configured to fit inside of a lens capsule and at least partially encircling a line of sight of an intraocular lens within the lens capsule. The device () can further include a semipermeable membrane () operatively coupled to the active agent reservoir (), where the semipermeable membrane () is configured to allow diffusion of an active agent from the active agent reservoir (). Additionally, a valve () can be operatively coupled to the active agent reservoir (), where the valve () is configured to allow filling of the active agent reservoir () with an active agent.

Growing community of inventors

Sandy, UT, United States of America

Balamurali Krishna Ambati